Medifast (MED) 10-Q 9 Nov 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 01, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Entity Registrant Name	MEDIFAST INC
Entity Central Index Key	910,329
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		11,848,360

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 57,120	$ 42,037
Accounts receivable-net of allowance for sales returns and doubtful accounts of $458 and $417	1,131	1,633
Inventory	15,015	13,335
Investment securities	24,936	25,072
Income taxes, prepaid		1,549
Prepaid expenses and other current assets	3,027	2,886
Deferred tax assets	1,941	1,208
Current assets of discontinued operations		353
Total current assets	103,170	88,073
Property, plant and equipment - net	20,111	29,029
Other assets	162	205
Long-term assets of discontinued operations	15	19
TOTAL ASSETS	123,458	117,326
Current liabilities:
Accounts payable and accrued expenses	24,418	22,504
Income taxes payable	1,244
Current maturities of capital leases	56	219
Current liabilities of discontinued operations	294	841
Total current liabilities	26,012	23,564
Other liabilities:
Deferred tax liabilities	2,510	4,890
Long-term liabilities of discontinued operations	7	288
Total liabilities	28,529	28,742
Stockholders' Equity:
Common stock; par value $.001 per share; 20,000 shares authorized; 12,025 and 12,014 issued at September 30, 2016 and December 31, 2015, respectively 11,848 and 11,797 outstanding September 30, 2016 and December 31, 2015, respectively	12	12
Additional paid-in capital	1,588
Accumulated other comprehensive income/(loss)	69	(62)
Retained earnings	93,260	88,634
Total stockholders' equity	94,929	88,584
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 123,458	$ 117,326

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Accounts receivable, allowance for sales returns and doubtful accounts	$ 458	$ 417
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	20,000,000	20,000,000
Common stock, issued	12,025,000	12,014,000
Common stock, outstanding	11,848,000	11,797,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Revenue	$ 68,578	$ 65,936	$ 212,067	$ 211,461
Cost of sales	16,415	16,776	53,485	55,364
Gross Profit	52,163	49,160	158,582	156,097
Selling, general, and administrative	43,210	41,185	138,337	132,947
Income from operations	8,953	7,975	20,245	23,150
Other income (expense)
Interest and dividend income, net	60	154	240	450
Other income (expense)	(2)	(20)	(23)	129
Nonoperating Income (Expense)	58	134	217	579
Income from continuing operations before income taxes	9,011	8,109	20,462	23,729
Provision for income taxes	2,946	2,707	6,740	8,064
Income from continuing operations	6,065	5,402	13,722	15,665
Income from discontinued operations, net of tax		104		533
Net income	$ 6,065	$ 5,506	$ 13,722	$ 16,198
Basic earnings per share
Earnings per share from continuing operations	$ 0.51	$ 0.45	$ 1.16	$ 1.30
Earnings per share from discontinued operations		0.01		0.05
Earnings per share	0.51	0.46	1.16	1.35
Diluted earnings per share
Earnings per share from continuing operations	0.51	0.45	1.15	1.29
Earnings per share from discontinued operations		0.01		0.05
Earnings per share	$ 0.51	$ 0.46	$ 1.15	$ 1.34
Weighted average shares outstanding -
Basic	11,848	11,923	11,839	12,028
Diluted	11,948	12,020	11,925	12,122
Cash dividends declared per share	$ 0.25		$ 0.75

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statement Of Other Comprehensive Income [Abstract]
Net income	$ 6,065	$ 5,506	$ 13,722	$ 16,198
Other comprehensive income, net of tax
Change in foreign currency translation, net of tax	(3)		11
Change in fair value of marketable securities, net of tax	(52)	(294)	55	(282)
Adjustment for net (gains)/losses realized and included in net income, net of tax		(9)	65	(109)
Total change in unrealized losses on marketable securities, net of tax	(52)	(303)	120	(391)
Other comprehensive income (loss)	(55)	(303)	131	(391)
Comprehensive income	$ 6,010	$ 5,203	$ 13,853	$ 15,807

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - 9 months ended Sep. 30, 2016 - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid- In Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income [Member]	Total
Balance at Dec. 31, 2015	$ 12		$ 88,634	$ (62)	$ 88,584
Balance (in shares) at Dec. 31, 2015	12,014
Options exercised by executives and directors		$ 299			299
Options exercised by executives and directors (in shares)	12
Share-based compensation		1,870			1,870
Share-based compensation (in shares)	24
Net shares repurchased for employee taxes		(686)	(57)		(743)
Net shares repurchased for employee taxes (in shares)	(25)
Share-based compensation tax benefit		105			105
Cash dividends declared to stockholders			(9,039)		(9,039)
Net income			13,722		13,722
Other comprehensive income				131	131
Balance at Sep. 30, 2016	$ 12	$ 1,588	$ 93,260	$ 69	$ 94,929
Balance (in shares) at Sep. 30, 2016	12,025

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net income	$ 13,722	$ 16,198
Income from discontinued operations, net of tax		533
Income from continuing operations	13,722	15,665
Adjustments to reconcile net income to net cash provided by operating activities from continuing operations:
Depreciation and amortization	4,211	5,425
Realized (gain)/loss on investment securities, net	174	(117)
Share-based compensation	1,870	1,707
Deferred income taxes	(3,194)	163
Impairment of fixed assets	6,083
(Gain)/loss on disposal of fixed assets	(13)	59
Changes in assets and liabilities which provided (used) cash:
Accounts receivable	502	(219)
Inventory	(1,680)	3,965
Prepaid expenses and other current assets	(141)	1,158
Other assets	43	334
Accounts payable and accrued expenses	1,766	(1,676)
Income taxes	2,793	4,358
Net cash provided by operating activities- continuing operations	26,136	30,822
Net cash used in operating activities- discontinued operations	(471)	(3,525)
Net cash provided by operating activities	25,665	27,297
Cash Flow from Investing Activities:
Sale of investment securities	26,741	7,135
Purchase of investment securities	(26,578)	(6,987)
Sale of property and equipment	676
Purchase of property and equipment	(2,039)	(1,605)
Net cash used in investing activities- continuing operations	(1,200)	(1,457)
Net cash used in investing activities- discontinued operations
Net cash used in investing activities	(1,200)	(1,457)
Cash Flow from Financing Activities:
Repayment of capital leases	(163)	(173)
Decrease in note receivable		45
Net shares repurchased for employee taxes	(743)	(875)
Options exercised by executives and directors	299	44
Excess tax benefits from share-based compensation	105	170
Purchase of treasury stock		(10,516)
Cash dividends paid to stockholders	(8,891)
Net cash used in financing activities- continuing operations	(9,393)	(11,305)
Net cash used in financing activities- discontinued operations
Net cash used in financing activities	(9,393)	(11,305)
Foreign currency impact	11
NET CHANGE IN CASH AND CASH EQUIVALENTS	15,083	14,535
Cash and cash equivalents - beginning of the period	42,037	24,459
Cash and cash equivalents - end of period	57,120	38,994
Supplemental disclosure of cash flow information:
Interest paid	6	18
Income taxes paid	7,160	$ 1,805
Dividends declared included in accounts payable	$ 3,162

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2016
Basis of Presentation and Presentation of Financial Statements [Abstract]
Basis of Presentation	1. Basis of Presentation  The condensed unaudited interim consolidated financial statements included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, they do not include all of the information and footnotes required by GAAP for annual fiscal reporting periods. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included and management believes the disclosures that are made are adequate to make the information presented not misleading. The consolidated balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.  The results of operations for the three and nine months ended September 30, 2016 are not necessarily indicative of results that may be expected for the fiscal year ending December 31, 2016. The accompanying condensed unaudited interim consolidated financial statements should be read in conjunction with the 2015 audited financial statements and notes thereto, which are included in the Company’s Annual Report on Form 10-K filed for the fiscal year ended December 31, 2015 (“2015 Form 10-K”).

Presentation of Financial State

Presentation of Financial Statements	9 Months Ended
	Sep. 30, 2016
Basis of Presentation and Presentation of Financial Statements [Abstract]
Presentation of Financial Statements	2. Presentation of Financial Statements The condensed unaudited interim consolidated financial statements included herein include the accounts of Medifast, Inc. (the “Company”) and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2016
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	 3. Recent Accounting Pronouncements We have considered all new accounting pronouncements and have concluded that there are no new pronouncements that may have a material impact on our results of operations, financial condition, or cash flows, based on current information, except for: ASU 2016-09, Compensation- Stock Compensation (Topic 718): Improvements to Employee Share-Based Payable Accounting allows for the simplification of accounting for stock compensation in relation to income taxes, classification of awards as equity or liabilities and classification on the statement of cash flows. The pronouncement is effective for fiscal years beginning after December 15, 2016. The pronouncement is not expected to have a material impact on the Company’s financial statements. ASU 2016-02, Leases (Topic 842) requires the rights and obligations of all leased assets with a term greater than 12 months to be presented on the balance sheet. The pronouncement is effective for fiscal years beginning after December 15, 2018. Management is currently evaluating the effect that the pronouncements of ASU 2016-02 will have on the Company’s financial statements. ASU 2016-01, Financial Instruments- Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities , most notably requires the changes in fair value of equity investments to be recognized in net income. The pronouncement also requires the use of the exit price notion, the separate presentation of financial assets and liabilities by measurement category and form of asset, and the separate presentation in other comprehensive income of changes in fair value resulting from a change in the instrument-specific credit risk. The pronouncement is effective for fiscal years beginning after December 15, 2017. Based on the risk level of the Company’s investment portfolio, Management does not expect the pronouncement to have a material impact on the Company’s financial statements. ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes requires the Company to classify all deferred tax assets and deferred tax liabilities as noncurrent. The pronouncement is effective for fiscal years beginning after December 15, 2016. The pronouncement will result in a reclassification on the condensed consolidated balance sheet but is not expected to have any other material impacts on the Company’s financial statements. ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory , requires the Company to recognize inventory at the lower of cost and net realizable value. Net realizable value is defined as the estimated selling price in the ordinary course of business less costs of completion, disposal, and transportation. The pronouncement is effective for fiscal years beginning after December 31, 2016. The pronouncement is not expected to have a material impact on the Company’s financial statements. ASU 2015-09, Revenue from Contracts with Customers (Topic 606) , requires the Company to recognize revenue for the transfer of goods or services to customers for the amount the Company expects to be entitled to in exchange for those goods or services. The Company will be required to identify the contract, identify the relevant performance obligations, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when the entity satisfies a performance obligation. The pronouncements of this ASU are effective for interim and annual periods beginning after December 15, 2017. Management is still evaluating the effect that the pronouncements of ASU 2015-09 will have on the Company’s financial statements but does not expect it to have a material impact.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2016
Revenue Recognition [Abstract]
Revenue Recognition	4. Revenue Recognition Revenue is recognized net of discounts, rebates, promotional adjustments, price adjustments, and estimated returns and upon transfer of title and risk to the customer which primarily occurs at shipping (F.O.B. terms). Upon shipment, the Company has no further performance obligations and collection is reasonably assured as the majority of sales are paid for prior to shipping. Revenue from our Franchise Medifast Weight Control Centers is primarily generated from product sales.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2016
Inventories [Abstract]
Inventories	5. Inventories Inventories consist principally of packaged meal replacements held in the Company’s warehouses. Inventory is stated at the lower of cost or market, utilizing the first-in, first-out method. The cost of finished goods includes the cost of raw materials, packaging supplies, direct and indirect labor and other indirect manufacturing costs. On a quarterly basis, management reviews inventory for unsalable or obsolete inventory. Inventories consisted of the following as of:    September 30, 2016 December 31, 2015  Raw Materials $ 4,922 $ 3,666  Packaging 933 788  Non-food Finished Goods 670 635  Finished Goods 8,976 8,545  Reserve for Obsolete Inventory (486) (299)  $ 15,015 $ 13,335  

Earnings per Share

Earnings per Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share	6. Earnings per Share Basic earnings per share (“EPS”) computations are calculated utilizing the weighted average number of shares of common stock outstanding during the periods presented. Diluted EPS is calculated utilizing the weighted average number of shares of common stock outstanding adjusted for the effect of dilutive common stock equivalents. The following table sets forth the computation of basic and diluted EPS:    Three Months Ended September 30, Nine Months Ended September 30,  2016 2015 2016 2015  Numerator:  Income from continuing operations $ 6,065 $ 5,402 $ 13,722 $ 15,665  Income from discontinued operations - 104 - 533  Net income $ 6,065 $ 5,506 $ 13,722 $ 16,198   Denominator:  Weighted average shares of common stock outstanding 11,848 11,923 11,839 12,028  Effect of dilutive common stock equivalents 100 97 86 94   Weighted average shares of common stock outstanding 11,948 12,020 11,925 12,122   EPS:  Basic earnings per share  Earnings per share from continuing operations $ 0.51 $ 0.45 $ 1.16 $ 1.30  Earnings per share from discontinued operations $ - $ 0.01 $ - $ 0.05  Earnings per share $ 0.51 $ 0.46 $ 1.16 $ 1.35   Diluted earnings per share  Earnings per share from continuing operations $ 0.51 $ 0.45 $ 1.15 $ 1.29  Earnings per share from discontinued operations $ - $ 0.01 $ - $ 0.05  Earnings per share $ 0.51 $ 0.46 $ 1.15 $ 1.34  The calculation of diluted earnings per share excluded 10,000 and 69,375 antidilutive options outstanding for the three months ended September 30, 2016 and 2015, respectively, and 87,500 and 74,373 antidilutive options outstanding for the nine months ended September 30, 2016 and 2015, respectively. EPS is computed independently for each of the quarters presented; accordingly, the sum of the quarterly earnings per common share may not equal the year-to-date total computed.

Estimates

Estimates	9 Months Ended
	Sep. 30, 2016
Estimates [Abstract]
Estimates	7. Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Financial Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2016
Financial Instruments [Abstract]
Financial Instruments	8. Financial Instruments  Certain financial assets and liabilities are accounted for at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy prioritizes the inputs used to measure fair value:  Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.  Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.  Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value from the perspective of a market participant.  The following table represents cash and the available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category recorded as cash and cash equivalents or investment securities as of:     September 30, 2016  Cost Unrealized Gains Unrealized Losses Accrued Interest Estimated Fair Value Cash & Cash Equivalents Investment Securities   Cash $ 56,886 $ - $ - $ - $ 56,886 $ 56,886 $ -   Level 1:  Money Market Accounts 234 - - - 234 234 -  Government & Agency Securities 2,661 2 (2) 4 2,665 - 2,665  2,895 2 (2) 4 2,899 234 2,665   Level 2:  Municipal Bonds 22,025 17 (28) 257 22,271 - 22,271  22,025 17 (28) 257 22,271 - 22,271   Total $ 81,806 $ 19 $ (30) $ 261 $ 82,056 $ 57,120 $ 24,936      December 31, 2015  Cost Unrealized Gains Unrealized Losses Accrued Interest Estimated Fair Value Cash & Cash Equivalents Investment Securities   Cash $ 38,276 $ - $ - $ - $ 38,276 $ 38,276 $ -   Level 1:  Money Market Accounts 3,761 - - - 3,761 3,761 -  Mutual Funds 9,654 37 (444) - 9,247 - 9,247  Corporate Equity Securities 1,332 246 (76) - 1,502 - 1,502  Government & Agency Securities 5,425 25 (19) 17 5,448 - 5,448  20,172 308 (539) 17 19,958 3,761 16,197   Level 2:  Municipal Bonds 2,735 42 (3) 20 2,794 - 2,794  Corporate Bonds 6,054 22 (41) 46 6,081 - 6,081  8,789 64 (44) 66 8,875 - 8,875   Total $ 67,237 $ 372 $ (583) $ 83 $ 67,109 $ 42,037 $ 25,072  The Company had a realized loss of $97 thousand and $17 thousand for the three months ended September 30, 2016 and 2015, respectively, and a realized loss of $174 thousand and a realized gain of $117 thousand for the nine months ended September 30, 2016 and 2015, respectively. As of September 30, 2016 and 2015, gross unrealized losses related to individual securities that had been in a continuous loss position for 12 months or longer were not significant. The maturities of the Company’s investment securities generally range up to 5 years for municipal bonds and for government and agency securities.

Shared-based Compensation

Shared-based Compensation	9 Months Ended
	Sep. 30, 2016
Share-Based Compensation [Abstract]
Shared-based Compensation	9. Shared-based Compensation Stock Options:  The Company has issued non-qualified and incentive stock options to employees and nonemployee directors. The fair value of these options are estimated on the date of grant using the Black-Scholes option pricing model, which requires estimates of the expected term of the option, the expected volatility of the price of the Company’s common stock, dividend yield and the risk-free interest rate. Options outstanding as of September 30, 2016 generally vest over a period of three years with an expiration term of ten years. The exercise price of these options ranges from $24.26 to $31.55 . The expected volatility is based on the historical volatility of the Company’s common stock over the period of time equivalent to the expected term for each award. Due to the Company’s lack of option exercise history, the expected term is calculated using the simplified method defined as the midpoint between the vesting period and the contractual term of each award. The risk free interest rate is based on the U.S. Treasury yield curve in effect on the date of grant which most closely corresponds to the expected term of the option. The Company declared its first dividend in December 2015; and therefore, a dividend yield was not utilized in the Black-Scholes calculation for options granted prior to December 2015. The weighted average input assumptions used and resulting fair values were as follows:     2016  Expected life (in years) 6  Risk-free interest rate 1.11%  Expected volatility 42.22%  Dividend yield 3.56%  The following table summarizes the stock option activity:     Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (Yrs) Aggregate Intrinsic Value  Outstanding at December 31, 2015 98 $ 28.17  Granted 50 27.99  Exercised (12) 25.64  Forfeited (6) 29.87  Expired - -  Outstanding at September 30, 2016 130 $ 28.22 8.45 $ 1,239  Exercisable at September 30, 2016 49 $ 27.45 7.56 $ 503  The weighted-average grant date fair value of options granted as of September 30, 2016 was $7.91 . The unrecognized compensation expense calculated under the fair value method for shares expected to vest as of September 30, 2016 was approximately $0.6 million and is expected to be recognized over a weighted average period of 1.8 years. No cash proceeds from the exercise of stock options were received during the three months ended September 30, 2016 and 2015. The Company received $0.3 million and $44 thousand in cash proceeds from the exercise of stock options during the nine months ended September 30, 2016 and 2015. Restricted Stock: The Company has issued restricted stock to employees and nonemployee directors generally with vesting terms up to five years after the date of grant. The fair value is equal to the market price of the Company’s common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period. The following table summarizes the restricted stock activity:     Shares Weighted-Average Grant Date Fair Value  Unvested at December 31, 2015 264 $ 26.38  Granted 17 28.35  Vested (65) 25.14  Forfeited (39) 26.43  Unvested at September 30, 2016 177 $ 27.02 The total costs of the options and restricted stock awards charged against income during the three months ended September 30, 2016 and 2015 w ere $678 thousand and $602 thousand, respectively, and $1.9 million and $1.7 million for the nine months ended September 30, 2016 and 2015, respectively. The Company accrued an additional $248 thousand and $156 thousand for performance-based restricted stock awards for the three months ended September 30, 2016 and 2015, respectively, and $613 thousand and $634 thousand for the nine months ended September 30, 2016 and 2015, respectively. The cost of the 2016 performance awards will depend on management’s achievement of pre-determined performance targets and the Company’s fiscal 2016 performance and will be finalized and approved at the first Board of Directors meeting in 2017. The cost recognized during the three months ended September 30, 2016 is based on the performance that management expects the Company will achieve as of September 30, 2016. The total income tax benefit recognized in the consolidated statements of income for restricted stock awards was approximately $228 thousand and $212 thousand for the three months ended September 30, 2016 and 2015, respectively and $622 thousand and $602 thousand for the nine months ended September 30, 2016 and 2015. The total tax benefit recognized in additional paid-in capital upon vesting of restricted stock awards and exercise of stock options for the three months ended September 30, 2015 was $5 thousand, and $105 thousand and $170 thousand for the nine months ended September 30, 2016 and 2015, respectively. No tax benefit was recognized in additional paid-in capital upon vesting of restricted stock awards and exercise of stock options for the three months ended September 30, 2016. There was approximately $2.5 million of total unrecognized compensation cost related to restricted stock awards as of September 30, 2016. The cost is expected to be recognized over a weighted-average period of approximately 1.8 years , respectively .  On October 3, 2016, the Company granted an award for an additional 16,061 of time-based restricted shares and 210,000 deferred shares that vest based on certain market and performance conditions to an executive. The cost of the award is $2.6 million and will be recognized through December 2019 .

Business Segments

Business Segments	9 Months Ended
	Sep. 30, 2016
Business Segments [Abstract]
Business Segments	10. Business Segments  Operating segments are components of an enterprise about which separate financial information is available that is regularly reviewed by the chief operating decision maker about how to allocate resources and in assessing performance. The consolidated operating profit of the Company is reviewed by the chief operating decision maker as a single segment and sales are reviewed at the business unit level.  The following table presents sales by business unit for the:     Three Months Ended September 30, Nine Months Ended September 30,  2016 2015 2016 2015   Take Shape For Life $ 56,509 $ 49,883 $ 170,594 $ 154,243  Medifast Direct 8,104 11,271 28,355 39,388  MWCC- Franchise 3,692 4,011 12,047 13,348  Medifast Wholesale 273 771 1,071 4,482  Revenue $ 68,578 $ 65,936 $ 212,067 $ 211,461  

Discontinued Operations, Exit A

Discontinued Operations, Exit Activities, and Clinic Obligations	9 Months Ended
	Sep. 30, 2016
Discontinued Operations, Exit Activities, and Clinic Obligations [Abstract]
Discontinued Operations, Exit Activities, and Clinic Obligations	11. Discontinued Operations, Exit Activities, and Clinic Obligations  In 2014, the Company exited the Medifast Weight Control corporate center model by selling 41 company owned centers to existing franchise partners ( 24 centers were sold in June 2014 and the remaining 17 centers were sold in December 2014) and clo sure of the remaining 34 corporate centers. In accordance with ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity the assets, liabilities, operating results, and cash flows of the corporate Medifast Weight Control Center business unit have been presented separately as discontinued operations in the Consolidated Financial Statements for all periods presented.  The following is a summary of the Company’s operating results for discontinued operations for the:     Three Months Ended September 30, Nine Months Ended September 30,  2016 2015 2016 2015   Income before income taxes from discontinued operations $ - $ 140 $ - $ 834  Income tax provision - 36 - 301  Income from discontinued operations, net of tax $ - $ 104 $ - $ 533   The following table presents the aggregate carrying amounts of the major classes of assets and liabilities included in discontinued operations as of:     September 30, 2016  ASSETS  Current assets:  Other assets $ 15   Total assets $ 15   LIABILITIES  Current liabilities:  Accounts payable and accrued expenses $ 294  Total current liabilities 294   Long-term lease obligations 7   Total liabilities $ 301 The following table summarizes the exit obligations, primarily for lease obligations related to closed corporate Medifast Weight Control Centers, severance accruals, and customer refunds incurred as of September 30, 2016:     Ending accrued balance as of December 31, 2015 $ 1,129  Adjustments recorded during the period (1) 192  Payments during the period (1,020)  Ending accrued balance as of September 30, 2016 $ 301   (1)- The adjustments to the accrual recorded in 2016 relate primarily to agreements reached with franchisees related to lease obligations for previously owned MWCC Corporate Centers.  These charges were recorded in the balance sheet as of September 30, 2016 as follows:     Total current liabilities of discontinued operations $ 294  Total long-term liabilities of discontinued operations 7  Ending accrued balance as of September 30, 2016 $ 301  

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2016
Restructuring [Abstract]
Restructuring	12. Restructuring During the first quarter of 2016, the Company announced the departure of three Executive Vice Presidents in an effort to re-align the senior leadership team to reflect the changing needs of the business and to provide greater emphasis on the Company’s key areas of focus, and also the resignation of the Company’s President and Chief Operating Officer. The Company incurred $1.2 million in net restructuring costs in selling, general, and administrative expense associated with the departure of these four executives. This includes a $0.2 million reversal of costs accrued in 2015 for deferred shares that were granted in connection with the 2015 bonus plan and were forfeited as a result of their departure. The following table summarizes the severance accruals incurred as of September 30, 2016, excluding the reversal of prior year stock accrual:     Ending accrued balance as of December 31, 2015 $ -  Charges incurred during the period 1,343  Payments during the period (698)  Ending accrued balance as of September 30, 2016 $ 645  

Impairment

Impairment	9 Months Ended
	Sep. 30, 2016
Impairment [Abstract]
Impairment	13. Impairment During the second quarter of 2016, the Company incurred a $6.1 million impairment charge in connection with the abandonment of software under development for the Take Shape For Life® business unit. The decision to abandon the software, which was determined in the final stages of the quarterly close process, was the result of an in depth analysis of proven alternatives available today in the market which are a better fit for our business going forward and the cost of these alternatives when compared to the ongoing development and maintenance of the abandoned software. The impairment charge was recorded for the full value of the asset and has been included as part of selling, general, and administrative expense on the condensed consolidated statements of income.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2016
Inventories [Abstract]
Inventories	Inventories consisted of the following as of:    September 30, 2016 December 31, 2015  Raw Materials $ 4,922 $ 3,666  Packaging 933 788  Non-food Finished Goods 670 635  Finished Goods 8,976 8,545  Reserve for Obsolete Inventory (486) (299)  $ 15,015 $ 13,335 

Earnings per Share (Tables)

Earnings per Share (Tables)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share, Basic and Diluted	The following table sets forth the computation of basic and diluted EPS:    Three Months Ended September 30, Nine Months Ended September 30,  2016 2015 2016 2015  Numerator:  Income from continuing operations $ 6,065 $ 5,402 $ 13,722 $ 15,665  Income from discontinued operations - 104 - 533  Net income $ 6,065 $ 5,506 $ 13,722 $ 16,198   Denominator:  Weighted average shares of common stock outstanding 11,848 11,923 11,839 12,028  Effect of dilutive common stock equivalents 100 97 86 94   Weighted average shares of common stock outstanding 11,948 12,020 11,925 12,122   EPS:  Basic earnings per share  Earnings per share from continuing operations $ 0.51 $ 0.45 $ 1.16 $ 1.30  Earnings per share from discontinued operations $ - $ 0.01 $ - $ 0.05  Earnings per share $ 0.51 $ 0.46 $ 1.16 $ 1.35   Diluted earnings per share  Earnings per share from continuing operations $ 0.51 $ 0.45 $ 1.15 $ 1.29  Earnings per share from discontinued operations $ - $ 0.01 $ - $ 0.05  Earnings per share $ 0.51 $ 0.46 $ 1.15 $ 1.34 

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2016
Financial Instruments [Abstract]
Cash and Available for Sale Securities Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses, and Fair Value by Significant Investment Category	The following table represents cash and the available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category recorded as cash and cash equivalents or investment securities as of:     September 30, 2016  Cost Unrealized Gains Unrealized Losses Accrued Interest Estimated Fair Value Cash & Cash Equivalents Investment Securities   Cash $ 56,886 $ - $ - $ - $ 56,886 $ 56,886 $ -   Level 1:  Money Market Accounts 234 - - - 234 234 -  Government & Agency Securities 2,661 2 (2) 4 2,665 - 2,665  2,895 2 (2) 4 2,899 234 2,665   Level 2:  Municipal Bonds 22,025 17 (28) 257 22,271 - 22,271  22,025 17 (28) 257 22,271 - 22,271   Total $ 81,806 $ 19 $ (30) $ 261 $ 82,056 $ 57,120 $ 24,936      December 31, 2015  Cost Unrealized Gains Unrealized Losses Accrued Interest Estimated Fair Value Cash & Cash Equivalents Investment Securities   Cash $ 38,276 $ - $ - $ - $ 38,276 $ 38,276 $ -   Level 1:  Money Market Accounts 3,761 - - - 3,761 3,761 -  Mutual Funds 9,654 37 (444) - 9,247 - 9,247  Corporate Equity Securities 1,332 246 (76) - 1,502 - 1,502  Government & Agency Securities 5,425 25 (19) 17 5,448 - 5,448  20,172 308 (539) 17 19,958 3,761 16,197   Level 2:  Municipal Bonds 2,735 42 (3) 20 2,794 - 2,794  Corporate Bonds 6,054 22 (41) 46 6,081 - 6,081  8,789 64 (44) 66 8,875 - 8,875   Total $ 67,237 $ 372 $ (583) $ 83 $ 67,109 $ 42,037 $ 25,072 

Shared-based Compensation (Tabl

Shared-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2016
Share-Based Compensation [Abstract]
Schedule of Assumptions Used	The weighted average input assumptions used and resulting fair values were as follows:     2016  Expected life (in years) 6  Risk-free interest rate 1.11%  Expected volatility 42.22%  Dividend yield 3.56% 
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes the stock option activity:     Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (Yrs) Aggregate Intrinsic Value  Outstanding at December 31, 2015 98 $ 28.17  Granted 50 27.99  Exercised (12) 25.64  Forfeited (6) 29.87  Expired - -  Outstanding at September 30, 2016 130 $ 28.22 8.45 $ 1,239  Exercisable at September 30, 2016 49 $ 27.45 7.56 $ 503 
Restricted Stock Activity	The following table summarizes the restricted stock activity:     Shares Weighted-Average Grant Date Fair Value  Unvested at December 31, 2015 264 $ 26.38  Granted 17 28.35  Vested (65) 25.14  Forfeited (39) 26.43  Unvested at September 30, 2016 177 $ 27.02 

Business Segments (Tables)

Business Segments (Tables)	9 Months Ended
	Sep. 30, 2016
Business Segments [Abstract]
Segment Information	The following table presents sales by business unit for the:     Three Months Ended September 30, Nine Months Ended September 30,  2016 2015 2016 2015   Take Shape For Life $ 56,509 $ 49,883 $ 170,594 $ 154,243  Medifast Direct 8,104 11,271 28,355 39,388  MWCC- Franchise 3,692 4,011 12,047 13,348  Medifast Wholesale 273 771 1,071 4,482  Revenue $ 68,578 $ 65,936 $ 212,067 $ 211,461 

Discontinued Operations, Exit26

Discontinued Operations, Exit Activities, And Clinic Obligations (Tables)	9 Months Ended
	Sep. 30, 2016
Discontinued Operations, Exit Activities, and Clinic Obligations [Abstract]
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures	The following is a summary of the Company’s operating results for discontinued operations for the:     Three Months Ended September 30, Nine Months Ended September 30,  2016 2015 2016 2015   Income before income taxes from discontinued operations $ - $ 140 $ - $ 834  Income tax provision - 36 - 301  Income from discontinued operations, net of tax $ - $ 104 $ - $ 533   The following table presents the aggregate carrying amounts of the major classes of assets and liabilities included in discontinued operations as of:     September 30, 2016  ASSETS  Current assets:  Other assets $ 15   Total assets $ 15   LIABILITIES  Current liabilities:  Accounts payable and accrued expenses $ 294  Total current liabilities 294   Long-term lease obligations 7   Total liabilities $ 301 
Schedule of Accrued Liabilities	The following table summarizes the exit obligations, primarily for lease obligations related to closed corporate Medifast Weight Control Centers, severance accruals, and customer refunds incurred as of September 30, 2016:     Ending accrued balance as of December 31, 2015 $ 1,129  Adjustments recorded during the period (1) 192  Payments during the period (1,020)  Ending accrued balance as of September 30, 2016 $ 301   (1)- The adjustments to the accrual recorded in 2016 relate primarily to agreements reached with franchisees related to lease obligations for previously owned MWCC Corporate Centers.  These charges were recorded in the balance sheet as of September 30, 2016 as follows:     Total current liabilities of discontinued operations $ 294  Total long-term liabilities of discontinued operations 7  Ending accrued balance as of September 30, 2016 $ 301 

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2016
Restructuring [Abstract]
Restructuring and Related Costs	The following table summarizes the severance accruals incurred as of September 30, 2016, excluding the reversal of prior year stock accrual:     Ending accrued balance as of December 31, 2015 $ -  Charges incurred during the period 1,343  Payments during the period (698)  Ending accrued balance as of September 30, 2016 $ 645 

Inventories (Detail)

Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Inventories [Abstract]
Raw Materials	$ 4,922	$ 3,666
Packaging	933	788
Non-food Finished Goods	670	635
Finished Goods	8,976	8,545
Reserve for Obsolete Inventory	(486)	(299)
Inventory	$ 15,015	$ 13,335

Earnings per Share (Narrative)

Earnings per Share (Narrative) (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Earnings Per Share [Abstract]
Anti-dilutive options	10,000	69,375	87,500	74,373

Earnings per Share (Earnings pe

Earnings per Share (Earnings per Share) (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Numerator:
Income from continuing operations	$ 6,065	$ 5,402	$ 13,722	$ 15,665
Income from discontinued operations		104		533
Net income	$ 6,065	$ 5,506	$ 13,722	$ 16,198
Denominator:
Weighted average shares of common stock outstanding	11,848	11,923	11,839	12,028
Effect of dilutive common stock equivalents	100	97	86	94
Weighted average shares of common stock outstanding	11,948	12,020	11,925	12,122
Basic earnings per share
Earnings per share from continuing operations	$ 0.51	$ 0.45	$ 1.16	$ 1.30
Earnings per share from discontinued operations		0.01		0.05
Earnings per share	0.51	0.46	1.16	1.35
Diluted earnings per share
Earnings per share from continuing operations	0.51	0.45	1.15	1.29
Earnings per share from discontinued operations		0.01		0.05
Earnings per share	$ 0.51	$ 0.46	$ 1.15	$ 1.34

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Financial Instruments [Line Items]
Realized Gain (Loss) on Marketable Securities, Cost Method Investments, and Other Investments	$ (97)	$ (17)	$ (174)	$ 117
US Treasury and Government Short-term Debt Securities [Member]
Financial Instruments [Line Items]
Available for Sale Securities Maturity Period			5 years

Financial Instruments (Cash and

Financial Instruments (Cash and Available for Sale Securities Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses, and Fair Value by Significant Investment Category) (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	$ 81,806	$ 67,237
Unrealized Gains	19	372
Unrealized Losses	(30)	(583)
Accrued Interest	261	83
Estimated Fair Value	82,056	67,109
Cash & Cash Equivalents	57,120	42,037	$ 38,994	$ 24,459
Investment Securities	24,936	25,072
Cash [Member]
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	56,886	38,276
Estimated Fair Value	56,886	38,276
Cash & Cash Equivalents	56,886	38,276
Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	2,895	20,172
Unrealized Gains	2	308
Unrealized Losses	(2)	(539)
Accrued Interest	4	17
Estimated Fair Value	2,899	19,958
Cash & Cash Equivalents	234	3,761
Investment Securities	2,665	16,197
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	234	3,761
Estimated Fair Value	234	3,761
Cash & Cash Equivalents	234	3,761
Fair Value, Inputs, Level 1 [Member] | Mutual Funds [Member]
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost		9,654
Unrealized Gains		37
Unrealized Losses		(444)
Estimated Fair Value		9,247
Investment Securities		9,247
Fair Value, Inputs, Level 1 [Member] | Corporate Equity Securities [Member]
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost		1,332
Unrealized Gains		246
Unrealized Losses		(76)
Estimated Fair Value		1,502
Investment Securities		1,502
Fair Value, Inputs, Level 1 [Member] | Government and Agency Securities [Member]
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	2,661	5,425
Unrealized Gains	2	25
Unrealized Losses	(2)	(19)
Accrued Interest	4	17
Estimated Fair Value	2,665	5,448
Investment Securities	2,665	5,448
Fair Value, Inputs, Level 2 [Member]
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	22,025	8,789
Unrealized Gains	17	64
Unrealized Losses	(28)	(44)
Accrued Interest	257	66
Estimated Fair Value	22,271	8,875
Investment Securities	22,271	8,875
Fair Value, Inputs, Level 2 [Member] | Municipal Bonds [Member]
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	22,025	2,735
Unrealized Gains	17	42
Unrealized Losses	(28)	(3)
Accrued Interest	257	20
Estimated Fair Value	22,271	2,794
Investment Securities	$ 22,271	2,794
Fair Value, Inputs, Level 2 [Member] | Corporate Bonds
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost		6,054
Unrealized Gains		22
Unrealized Losses		(41)
Accrued Interest		46
Estimated Fair Value		6,081
Investment Securities		$ 6,081

Shared-based Compensation (Narr

Shared-based Compensation (Narrative) (Detail) - USD ($) $ / shares in Units, $ in Thousands	Oct. 03, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		$ 678	$ 602	$ 1,870	$ 1,707
Proceeds from stock options exercised				299	44
Share-based compensation tax benefit				$ 105
Terms of the award				The cost of the award is $2.6 million and will be recognized through December 2019.
Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cost of the award	$ 2,600
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total income tax benefit recognized related to restricted stock awards		228	212	$ 622	602
Employee service share based compensation nonvested awards total compensation cost not yet recognized		2,500		$ 2,500
Compensation cost recognition weighted average period				1 year 9 months 18 days
Share based compensation expense		248	156	$ 613	634
Award vesting period				5 years
Share-based compensation tax benefit		0	5	$ 105	170
Shares granted				17,000
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share based compensation nonvested awards total compensation cost not yet recognized		600		$ 600
Compensation cost recognition weighted average period				1 year 9 months 18 days
Award vesting period				3 years
Share-based compensation, shares authorized under stock option plans, exercise price range, lower range limit				$ 24.26
Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value				7.91
Share-based compensation, shares authorized under stock option plans, exercise price range, upper range limit				$ 31.55
Proceeds from stock options exercised		$ 0	$ 0	$ 300	$ 44
Share based compensation arrangement by share based payment award options expiration term				10 years
Time-Based Restircted Shares [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted	16,061
Deferred Shares [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted	210,000

Shared-based Compensation (Sche

Shared-based Compensation (Schedule of Assumptions Used) (Detail)	9 Months Ended
	Sep. 30, 2016
Share-Based Compensation [Abstract]
Expected life (in years)	6 years
Risk-free interest rate	1.11%
Expected volatility	42.22%
Dividend yield	3.56%

Shared-based Compensation (Sc35

Shared-based Compensation (Schedule of Share Based Compensation Stock Options Activity) (Detail) - Stock Option [Member] $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, Outstanding Beginning Balance | shares	98
Shares, Granted | shares	50
Shares, Exercised | shares	(12)
Shares, Forfeited | shares	(6)
Shares, Expired | shares
Shares, Outstanding Ending Balance | shares	130
Shares, Exerciseable | shares	49
Weighted-Average Exercise Price, Outstanding Beginning Balance | $ / shares	$ 28.17
Weighted-Average Exercise Price, Granted | $ / shares	27.99
Weighted-Average Exercise Price, Exercised | $ / shares	25.64
Weighted-Average Exercise Price, Forfeited | $ / shares	29.87
Weighted-Average Exercise Price, Expired | $ / shares
Weighted-Average Exercise Price, Oustanding Ending Balance | $ / shares	28.22
Weighted-Average Exercise Price, Exerciseable | $ / shares	$ 27.45
Weighted-Average Remaining Contractual Life (Yrs), Outstanding	8 years 5 months 12 days
Weighted-Average Remaining Contractual Life (Yrs), Exerciseable	7 years 6 months 22 days
Aggregate Intrinsic Value, Outstanding | $	$ 1,239
Aggregate Intrinsic Value, Exerciseable | $	$ 503

Shared-based Compensation (Summ

Shared-based Compensation (Summary of Restricted Stock Activity) (Detail) - Restricted Stock [Member] shares in Thousands	9 Months Ended
	Sep. 30, 2016$ / sharesshares
Shares
Unvested at December 31, 2015 | shares	264
Granted | shares	17
Vested | shares	(65)
Forfeited | shares	(39)
Unvested at September 30, 2016 | shares	177
Weighted-Average Grant Date Fair Value
Unvested at December 31, 2015 | $ / shares	$ 26.38
Granted | $ / shares	28.35
Vested | $ / shares	25.14
Forfeited | $ / shares	26.43
Unvested at September 30, 2016 | $ / shares	$ 27.02

Business Segments (Sales by Cha

Business Segments (Sales by Channel) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Net Revenue	$ 68,578	$ 65,936	$ 212,067	$ 211,461
Take Shape For Life [Member]
Segment Reporting Information [Line Items]
Net Revenue	56,509	49,883	170,594	154,243
Medifast Direct [Member]
Segment Reporting Information [Line Items]
Net Revenue	8,104	11,271	28,355	39,388
Franchise Weight Control Centers [Member]
Segment Reporting Information [Line Items]
Net Revenue	3,692	4,011	12,047	13,348
Medifast Wholesale [Member]
Segment Reporting Information [Line Items]
Net Revenue	$ 273	$ 771	$ 1,071	$ 4,482

Discontinued Operations, Exit38

Discontinued Operations, Exit Activities, and Clinic Obligations (Narrative) (Detail) - store	1 Months Ended		12 Months Ended
	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2014
Discontinued Operations, Exit Activities, and Clinic Obligations [Abstract]
Corporate Centers Sold During Period	17	24	41
Corporate Centers Closed During Period			34

Discontinued Operations, Exit39

Discontinued Operations, Exit Activities, and Clinic Obligations (Summary of Company's Operating Results for Discontinued Operations) (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Discontinued Operations, Exit Activities, and Clinic Obligations [Abstract]
Income before income taxes from discontinued operations	$ 140	$ 834
Income tax provision	36	301
Income from discontinued operations, net of tax	$ 104	$ 533

Discontinued Operations, Exit40

Discontinued Operations, Exit Activities, and Clinic Obligations (Major Classes of Assets and Liabilities) (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Other assets	$ 15
Total assets	15
Current liabilities:
Accounts payable and accrued expenses	294
Total current liabilities	294	$ 841
Long-term lease obligations	7
Total liabilities	$ 301

Discontinued Operations, Exit41

Discontinued Operations, Exit Activities, and Clinic Obligations (Summary of Accrued) (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Discontinued Operations, Exit Activities, and Clinic Obligations [Abstract]
Accrued Balance	$ 1,129
Adjustments recorded during the period	192	[1]
Payments during the period	(1,020)
Accrued Balance	$ 301
[1]	The adjustments to the accrual recorded in 2016 relate primarily to agreements reached with franchisees related to lease obligations for previously owned MWCC Corporate Centers.

Discontinued Operations, Exit42

Discontinued Operations, Exit Activities, and Clinic Obligations (Discontinued Operations Accrued Balance) (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Discontinued Operations, Exit Activities, and Clinic Obligations [Abstract]
Total current liabilities of discontinued operations	$ 294
Total long-term liabilities of discontinued operations	7	$ 288
Ending accrued balance as of September 30, 2016	$ 301

Restructuring (Narrative) (Deta

Restructuring (Narrative) (Detail) - Bonus Plan 2015 [Member] $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)
Restructuring Cost and Reserve [Line Items]
Accrued costs reversal	$ 0.2
Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost	$ 1.2

Restructuring (Severance Accrua

Restructuring (Severance Accruals Incurred) (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Restructuring [Abstract]
Ending accrued balance as of December 31, 2015
Charges incurred during the period	1,343
Payments during the period	(698)
Ending accrued balance as of September 30, 2016	$ 645

Impairment (Narrative) (Detail)

Impairment (Narrative) (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Jun. 30, 2016	Sep. 30, 2016
Impairment [Abstract]
Impairment of Long-Lived Assets Held-for-use	$ 6,100	$ 6,083